Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 0.31%.

  • ARS Pharmaceuticals' Return on Capital Employed fell 100.0% to 0.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.31%, marking a year-over-year decrease of 100.0%. This contributed to the annual value of 0.01% for FY2024, which is 2500.0% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.31% for Q3 2025, which was down 100.0% from 0.22% recorded in Q2 2025.
  • ARS Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.01% during Q4 2024, with a 5-year trough of 0.31% in Q3 2025.
  • Moreover, its 4-year median value for Return on Capital Employed was 0.25% (2023), whereas its average is 0.22%.
  • Per our database at Business Quant, ARS Pharmaceuticals' Return on Capital Employed crashed by -1500bps in 2023 and then soared by 2700bps in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.13% in 2022, then plummeted by -116bps to 0.28% in 2023, then surged by 96bps to 0.01% in 2024, then plummeted by -2529bps to 0.31% in 2025.
  • Its last three reported values are 0.31% in Q3 2025, 0.22% for Q2 2025, and 0.09% during Q1 2025.